An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura
- PMID: 22901913
- DOI: 10.1016/j.jpedsurg.2012.02.013
An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura
Abstract
Purpose: Indications and timing for splenectomy in pediatric chronic immune thrombocytopenic purpura (cITP) are controversial because of high spontaneous remission rates and concern for overwhelming postsplenectomy infection. The objective of this study was to assess the risks, costs, and benefits of medical and surgical intervention for children with cITP.
Methods: After receiving institutional review board approval, medical records for all children with cITP who underwent splenectomy from 2002 through 2009 were retrospectively reviewed (n = 22). Preoperative and postoperative data were collected. Medical and surgical costs were calculated based on pharmacy charges per dose and hospital charges, respectively.
Results: The median age at diagnosis was 11 years (range, 3-16 years). Medical management included steroids (n = 21), intravenous gamma globulin (n = 19), anti-D antibody (n = 19), or a combination of these therapies (n = 22). Nineteen patients (86%) reported side effects from medical therapy. Median age at splenectomy was 13 years (range, 6-18 years), and time to surgery was 23 months from diagnosis (range, 6-104 months). Splenectomy increased platelet counts in all children from a median of 25,500 to 380,000 postoperatively (P < .0001). One child experienced overwhelming postsplenectomy infection after a dog bite (n = 1). At the last follow-up (15 months; range, 1-79 months), 19 patients (86%) were asymptomatic with platelet counts greater than 50,000. Of the 3 children with persistent thrombocytopenia, 2 were diagnosed with secondary cITP. Median cost of splenectomy was significantly less than the cost of medical therapy ($20,803 vs $146,284; P < .0002).
Conclusion: Earlier surgical consultation for children with cITP may be justified given the high success rate and low morbidity, particularly given the significant complication rate and cost of continued medical treatment.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.Ann Hematol. 2002 Aug;81(8):436-40. doi: 10.1007/s00277-002-0488-x. Epub 2002 Jul 26. Ann Hematol. 2002. PMID: 12224000
-
Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China.Acta Haematol. 2006;115(1-2):39-45. doi: 10.1159/000089464. Acta Haematol. 2006. PMID: 16424648
-
Splenectomy for idiopathic thrombocytopenic purpura: a five-year retrospective review.Am Surg. 2000 Oct;66(10):952-4; discussion 955. Am Surg. 2000. PMID: 11261623
-
Management of chronic immune thrombocytopenic purpura in children and adults.Semin Hematol. 1998 Jan;35(1 Suppl 1):36-51. Semin Hematol. 1998. PMID: 9523748 Review.
-
Current options for the treatment of idiopathic thrombocytopenic purpura.Semin Hematol. 2007 Oct;44(4 Suppl 5):S12-23. doi: 10.1053/j.seminhematol.2007.11.003. Semin Hematol. 2007. PMID: 18096468 Review.
Cited by
-
Splenectomy for immune thrombocytopenia: down but not out.Blood. 2018 Mar 15;131(11):1172-1182. doi: 10.1182/blood-2017-09-742353. Epub 2018 Jan 2. Blood. 2018. PMID: 29295846 Free PMC article. Review.
-
Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases.Mediterr J Hematol Infect Dis. 2015 Oct 13;7(1):e2015057. doi: 10.4084/MJHID.2015.057. eCollection 2015. Mediterr J Hematol Infect Dis. 2015. PMID: 26543526 Free PMC article. Review.
-
Long-term efficacy and safety profile of splenectomy for pediatric chronic immune thrombocytopenia.Int J Hematol. 2023 May;117(5):774-780. doi: 10.1007/s12185-022-03529-z. Epub 2023 Jan 9. Int J Hematol. 2023. PMID: 36622550
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources